GSK has made a new drug submission (NDS) to Health Canada for the monoclonal antibody, depemokimab, targeting two specific ...

Market LaunchFormycon and Fresenius Kabi announce the commercial launch of FYB202/Otulfi™, an approved ustekinumab biosimilar in Canada 27.05.2025 / 14:30 CET/CESTThe issuer is solely responsible for ...

Ankyra Therapeutics is a biotech developing anchored immunotherapies aimed at enhancing the therapeutic window of ...

Inflammatory foods include red meat, processed foods, refined carbohydrates, fried food, and sugary drinks. They can cause ...

The Food and Drug Administration (FDA) has approved Nucala (mepolizumab) for the add-on maintenance treatment of adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD ...

Interleukin-4 receptor α (IL-4Rα), a shared receptor subunit for both IL-4 and IL-13, along with thymic stromal lymphopoietin ...

The FDA has approved Selarsdi (ustekinumab-aken) as interchangeable to the reference product Stelara (ustekinumab).

The FDA originally approved Otulfi as a biosimilar in October 2024 based on clinical data that demonstrated the product was highly similar to Stelara.

Memorial Sloan Kettering Cancer Center investigators report that T cell interferon-γ (IFNγ) orchestrates a dendritic-cell–natural-killer-cell circuit that suppresses leptomeningeal metastases in mouse ...

One such messenger is interleukin-12 (IL-12). Through meticulous analyses, research teams led by Professor Frank Heppner, Director of the Department of Neuropathology at Charité – Universitätsmedizin ...

One such messenger is interleukin-12 (IL-12). Through meticulous analyses, research teams led by Professor Frank Heppner, Director of the Department of Neuropathology at Charité ...